ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
ADMA Biologics issued a statement refuting allegations made by short seller Culper Research concerning competitive positioning, inventory management, and accounting practices. The company emphasized steady growth in demand and utilization of its ASCENIV immune globulin product over the past two years, inventory levels aligned with industry standard…